Imputation of response rates from means and standard deviations in schizophrenia

Schizophrenia Research

Volumn 151, Issue 1-3, 2013, Pages 209-214

  Samara, Myrto T ^a   Spineli, Loukia M ^b   Furukawa, Toshi A ^c   Engel, Rolf R ^d   Davis, John M ^e,f   Salanti, Georgia ^b   Leucht, Stefan ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF IOANNINA   (Greece)

^c KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^f MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

Continuous outcomes; Dichotomous outcomes; Meta analysis; Response; Risks; Standardized mean difference

Indexed keywords

AMISULPRIDE; NEUROLEPTIC AGENT; OLANZAPINE;

ACCURACY; ARTICLE; CALCULATION; CONTROLLED STUDY; CORRELATION COEFFICIENT; GEOMETRY; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS;

CONTINUOUS OUTCOMES; DICHOTOMOUS OUTCOMES; META-ANALYSIS; RESPONSE; RISKS; STANDARDIZED MEAN DIFFERENCE;

ANTIPSYCHOTIC AGENTS; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; MALE; META-ANALYSIS AS TOPIC; ODDS RATIO; PATIENT OUTCOME ASSESSMENT; REGRESSION ANALYSIS; SCHIZOPHRENIA;

EID: 84889085038     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.10.029     Document Type: Article

References (47)

1. Altman D.G., Royston P. The cost of dichotomising continuous variables. BMJ 2006, 332(7549):1080.
2. Altman D.G., Lausen B., Sauerbrei W., Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J. Natl. Cancer Inst. 1994, 86(11):829-835.
3. Beasley C.M., Sanger T., Satterlee W., Tollefson G., Tran P., Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 1996, 124(1-2):159-167.
4. Beasley C.M., Hamilton S.H., Crawford A.M., Dellva M.A., Tollefson G.D., Tran P.V., Blin O., Beuzen J.-N. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur. Neuropsychopharmacol. 1997, 7:125-137.
5. Bland J.M., Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986, 1(8476):307-310.
6. Bland J.M., Altman D.G. A note on the use of the intraclass correlation coefficient in the evaluation of agreement between two methods of measurement. Comput. Biol. Med. 1990, 20(5):337-340.
7. Bland J.M., Altman D.G. Measuring agreement in method comparison studies. Stat. Methods Med. Res. 1999, 8(2):135-160.
8. Breier A., Berg P.H., Thakore J.H., Naber D., Gattaz W.F., Cavazzoni P., Walker D.J., Roychowdhury S.M., Kane J.M. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am. J. Psychiatry 2005, 162(10):1879-1887.
9. Carriere P., Bonhomme D., Lemperiere T. Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). Eur. Psychiatry 2000, 15(5):321-329.
10. Chambers R.L. Evaluation Criteria for Statistical Editing and Imputation 2001, Office for National Statistics, Newport, Wales, Great Britain.
11. Chinn S. The assessment of methods of measurement. Stat. Med. 1990, 9(4):351-362.
12. Colonna L., Saleem P., Dondey-Nouvel L., Rein W. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. Int. Clin. Psychopharmacol. 2000, 15(1):13-22.
13. Cox D., Snell E. Analysis of Binary Data 1989, Chapman & Hall, London. Second ed.
14. da Costa B.R., Rutjes A.W., Johnston B.C., Reichenbach S., Nuesch E., Tonia T., Gemperli A., Guyatt G.H., Juni P. Methods to convert continuous outcomes into odds ratios of treatment response and numbers needed to treat: meta-epidemiological study. Int. J. Epidemiol. 2012, 41(5):1445-1459.
15. Donner A. Linear regression analysis with repeated measurements. J. Chronic Dis. 1984, 37(6):441-448.
16. Furukawa T.A., Leucht S. How to obtain NNT from Cohen's d: comparison of two methods. PLoS One 2011, 6(4):e19070.
17. Furukawa T.A., Cipriani A., Barbui C., Brambilla P., Watanabe N. Imputing response rates from means and standard deviations in meta-analyses. Int. Clin. Psychopharmacol. 2005, 20(1):49-52.
18. Hasselblad V., Hedges L.V. Meta-analysis of screening and diagnostic tests. Psychol. Bull. 1995, 117(1):167-178.
19. Horton N.J., White I.R., Carpenter J. The performance of multiple imputation for missing covariates relative to complete case analysis. Stat. Med. 2010, 29(12):1357. (author reply 1358).
20. Keating J., Matyas T. Unreliable inferences from reliable measurements. Aust. J. Physiother. 1998, 44(1):5-10.
21. Keefe R.S., Young C.A., Rock S.L., Purdon S.E., Gold J.M., Breier A. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr. Res. 2006, 81(1):1-15.
22. King T.S., Chinchilli V.M., Carrasco J.L. A repeated measures concordance correlation coefficient. Stat. Med. 2007, 26(16):3095-3113.
23. Kinon B.J., Noordsy D.L., Liu-Seifert H., Gulliver A.H., Ascher-Svanum H., Kollack-Walker S. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. J. Clin. Psychopharmacol. 2006, 26(5):453-461.
24. Kraemer H.C., Kupfer D.J. Size of treatment effects and their importance to clinical research and practice. Biol. Psychiatry 2006, 59(11):990-996.
25. Leucht S., Kane J.M., Kissling W., Hamann J., Etschel E., Engel R. Clinical implications of Brief Psychiatric Rating Scale scores. Br. J. Psychiatry 2005, 187:366-371.
26. Leucht S., Kane J.M., Kissling W., Hamann J., Etschel E., Engel R.R. What does the PANSS mean?. Schizophr. Res. 2005, 79(2-3):231-238.
27. Leucht S., Davis J.M., Engel R.R., Kane J.M., Wagenpfeil S. Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology 2007, 32(9):1903-1910.
28. Levine S.Z., Rabinowitz J., Engel R., Etschel E., Leucht S. Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI. Schizophr. Res. 2008, 98(1-3):318-322.
29. Lieberman J.A., Phillips M., Gu H., Stroup S., Zhang P., Kong L., Ji Z., Koch G., Hamer R.M. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs. chlorpromazine. Neuropsychopharmacology 2003, 28(5):995-1003.
30. Lieberman J.A., Tollefson G., Tohen M., Green A.I., Gur R.E., Kahn R., McEvoy J., Perkins D., Sharma T., Zipursky R., Wei H., Hamer R.M. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am. J. Psychiatry 2003, 160(8):1396-1404.
31. Lin L.I. A concordance correlation coefficient to evaluate reproducibility. Biometrics 1989, 45(1):255-268.
32. Mazumdar M., Smith A., Bacik J. Methods for categorizing a prognostic variable in a multivariable setting. Stat. Med. 2003, 22(4):559-571.
33. Moller H.J., Boyer P., Fleurot O., Rein W. Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group. Psychopharmacology (Berl) 1997, 132(4):396-401.
34. Obermeier M., Mayr A., Schennach-Wolff R., Seemuller F., Moller H.J., Riedel M. Should the PANSS be rescaled?. Schizophr. Bull. 2010, 36(3):455-460.
35. Obermeier M., Schennach-Wolff R., Meyer S., Moller H.J., Riedel M., Krause D., Seemuller F. Is the PANSS used correctly? A systematic review. BMC Psychiatry 2011, 11:113.
36. Peuskens J., Bech P., Moller H.J., Bale R., Fleurot O., Rein W. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride Study Group. Psychiatry Res. 1999, 88(2):107-117.
37. Puech A., Fleurot O., Rein W. Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. Acta Psychiatr. Scand. 1998, 98(1):65-72.
38. Rankin G., Stokes M. Reliability of assessment tools in rehabilitation: an illustration of appropriate statistical analyses. Clin. Rehabil. 1998, 12(3):187-199.
39. Royston P., Sauerbrei W., Altman D.G. Modeling the effects of continuous risk factors. J. Clin. Epidemiol. 2000, 53(2):219-221.
40. Schennach-Wolff R., Obermeier M., Seemuller F., Jager M., Schmauss M., Laux G., Pfeiffer H., Naber D., Schmidt L.G., Gaebel W., Klosterkotter J., Heuser I., Maier W., Lemke M.R., Ruther E., Klingberg S., Gastpar M., Engel R.R., Moller H.J., Riedel M. Does clinical judgment of baseline severity and changes in psychopathology depend on the patient population?. Results of a CGI and PANSS linking analysis in a naturalistic study. J Clin Psychopharmacol 2010, 30(6):726-731.
41. Sechter D., Peuskens J., Fleurot O., Rein W., Lecrubier Y. Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. Neuropsychopharmacology 2002, 27(6):1071-1081.
42. Shrout P.E., Fleiss J.L. Intraclass correlations: uses in assessing rater reliability. Psychol. Bull. 1979, 86(2):420-428.
43. Streiner D.L. Breaking up is hard to do: the heartbreak of dichotomizing continuous data. Can. J. Psychiatry 2002, 47(3):262-266.
44. Suissa S. Binary methods for continuous outcomes: a parametric alternative. J. Clin. Epidemiol. 1991, 44(3):241-248.
45. Tollefson G.D., Beasley C.M., Tran P.V., Street J.S., Krueger J.A., Tamura R.N., Graffeo K.A., Thieme M.E. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am. J. Psychiatry 1997, 154(4):457-465.
46. Tran P.V., Hamilton S.H., Kuntz A.J., Potvin J.H., Andersen S.W., Beasley C., Tollefson G.D. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J. Clin. Psychopharmacol. 1997, 17(5):407-418.
47. Wetzel H., Grunder G., Hillert A., Philipp M., Gattaz W.F., Sauer H., Adler G., Schroder J., Rein W., Benkert O. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology - a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group. Psychopharmacology (Berl) 1998, 137(3):223-232.